Drug Combination Details
| General Information of the Combination (ID: C95662) | |||||
|---|---|---|---|---|---|
| Name | Fisetin NP Info | + | Etoposide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Osteosarcoma
[ICD-11: 2B51]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | ||
| SaOS-2 | CVCL_0548 | Osteosarcoma | Homo sapiens | |||
| U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of fisetin with etoposide has higher anti-proliferative effects in osteosarcoma associated with cell cycle arrest, allowing the use of lower doses of the chemotherapeutic agent. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models. Arch Toxicol. 2018 Mar;92(3):1205-1214. | |||
